Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies
A Patrikidou, I Sinapi, H Regnault, F Fayard… - Investigational new …, 2014 - Springer
Background Sorafenib is the only systemic treatment that has shown a significant benefit in
overall survival (OS) and in progression-free survival (PFS) in advanced hepatocellular …
overall survival (OS) and in progression-free survival (PFS) in advanced hepatocellular …
First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a …
Y Liu, H Yue, S Xu, F Wang, N Ma, K Li, L Qiao… - International journal of …, 2015 - Springer
Background Because of the poor prognosis of unresectable or metastatic hepatocellular
carcinoma there is a need for effective systemic therapy. The purpose of this study was to …
carcinoma there is a need for effective systemic therapy. The purpose of this study was to …
Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study
A Zaanan, N Williet, M Hebbar, TS Dabakuyo… - Journal of …, 2013 - Elsevier
BACKGROUND & AIMS: The current standard treatment for advanced hepatocellular
carcinoma (HCC) is sorafenib. This drug is effective but generally does not induce tumor …
carcinoma (HCC) is sorafenib. This drug is effective but generally does not induce tumor …
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) results of a phase II study
S Louafi, V Boige, M Ducreux… - … Journal of the …, 2007 - Wiley Online Library
BACKGROUND New systemic therapies are needed to improve the prognosis of patients
with advanced‐stage hepatocellular carcinoma (HCC). In a Phase II trial involving …
with advanced‐stage hepatocellular carcinoma (HCC). In a Phase II trial involving …
Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis …
E Assenat, V Boige, S Thézenas, GP Pageaux… - 2013 - ascopubs.org
4028 Background: HCC is a vascular tumor with poor prognosis. Although S has been
shown to improve survival, its ability to induce tumor shrinkage is very low. Given the activity …
shown to improve survival, its ability to induce tumor shrinkage is very low. Given the activity …
Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open‐label, single‐arm phase II …
V Srimuninnimit, V Sriuranpong… - Asia‐Pacific Journal of …, 2014 - Wiley Online Library
Aims Currently, the only standard systemic treatment for advanced hepatocellular carcinoma
is sorafenib monotherapy. The study was conducted to assess the efficacy and safety of the …
is sorafenib monotherapy. The study was conducted to assess the efficacy and safety of the …
Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma (AHCC): results of a phase II study
4086 Background: New therapies are needed to improve the prognosis of patients (pts) with
AHCC. The rationale to develop the gemcitabine/oxaliplatin combination in AHCC is based …
AHCC. The rationale to develop the gemcitabine/oxaliplatin combination in AHCC is based …
Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
E Assenat, GP Pageaux, S Thézenas, JM Peron… - British Journal of …, 2019 - nature.com
Background Sorafenib remains one major first-line therapeutic options for advanced
hepatocellular carcinoma (aHCC), with modest efficacy. We investigated the addition of …
hepatocellular carcinoma (aHCC), with modest efficacy. We investigated the addition of …
[HTML][HTML] Efficacy and safety of sorafenib–gemcitabine combination therapy in advanced hepatocellular carcinoma: An open-label Phase II feasibility study
N Naqi, S Ahmad, S Murad, J Khattak - Hematology/oncology and stem cell …, 2014 - Elsevier
Purpose Sorafenib is considered a standard of care in advanced hepatocellular carcinoma
(HCC). Its combination with gemcitabine, a pyrimidine analogue with limited friendly hepatic …
(HCC). Its combination with gemcitabine, a pyrimidine analogue with limited friendly hepatic …
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib
O Mir, R Coriat, P Boudou-Rouquette, S Ropert… - Medical oncology, 2012 - Springer
Some patients with advanced hepatocellular carcinoma (HCC) progressing under sorafenib
remain eligible for further systemic therapy. Little is known on the feasibility of systemic …
remain eligible for further systemic therapy. Little is known on the feasibility of systemic …